Nakamura Kodai, Hiyake Naomi, Hamada Tomofumi, Yokoyama Seiya, Mori Kazuki, Yamashiro Kouta, Beppu Mahiro, Sagara Yasuaki, Sagara Yoshiaki, Sugiura Tsuyoshi
Department of Maxillofacial Diagnostic and Surgical Science, Field of Oral and Maxillofacial Rehabilitation, Graduate School of Medical and Dental Science, Kagoshima University, Kagoshima 890-8544, Japan.
Division of Maxillofacial Diagnostic and Surgical Sciences, Department of Oral and Maxillofacial Surgery, Graduate School of Dental Science, Kyushu University, Fukuoka 812-8582, Japan.
Cancers (Basel). 2021 Jan 25;13(3):449. doi: 10.3390/cancers13030449.
A lack of reliable biomarkers for oral squamous cell carcinoma (OSCC) poses a major clinical issue. The sensitivity and specificity of classical serum tumor markers, such as the squamous cell carcinoma antigen (SCC-Ag), are quite poor, especially for early detection. This study aimed to identify specific serum miRNAs potentially serving as OSCC biomarkers. The expression levels of candidate miRNAs in serum samples from 40 OSCC patients and 40 healthy controls were quantitatively analyzed via microarray and reverse transcription PCR (RT-PCR) analyses. To enhance the accuracy of detection, we used Fisher's linear discriminant analysis to establish a diagnostic model that incorporated a combination of selected miRNAs. Consequently, miR-19a and miR-20a were significantly upregulated in the patient group ( = 0.014 and 0.036, respectively), whereas miR-5100 was downregulated ( = 0.001). We found that a combination of six miRNAs (miR-24, miR-20a, miR-122, miR-150, miR-4419a, and miR-5100) could distinguish between OSCC and the control group with a higher degree of accuracy (Area Under the Curve, AUC: 0.844, sensitivity: 55%, and specificity: 92.5%). Furthermore, compared to serum SCC antigen, the 6-miRNA panel could accurately detect the presence of OSCC. The present specific miRNAs panel may serve as a novel candidate biomarker of oral cancer.
缺乏可靠的口腔鳞状细胞癌（OSCC）生物标志物是一个重大的临床问题。经典血清肿瘤标志物，如鳞状细胞癌抗原（SCC-Ag），其敏感性和特异性相当差，尤其是在早期检测方面。本研究旨在鉴定可能作为OSCC生物标志物的特异性血清微小RNA（miRNA）。通过微阵列和逆转录聚合酶链反应（RT-PCR）分析，对40例OSCC患者和40例健康对照血清样本中候选miRNA的表达水平进行了定量分析。为提高检测准确性，我们使用Fisher线性判别分析建立了一个纳入所选miRNA组合的诊断模型。结果显示，miR-19a和miR-20a在患者组中显著上调（分别为P = 0.014和0.036），而miR-5100下调（P = 0.001）。我们发现，六种miRNA（miR-24、miR-20a、miR-122、miR-150、miR-4419a和miR-5100）的组合能够以更高的准确性区分OSCC组和对照组（曲线下面积，AUC：0.844，敏感性：55%，特异性：92.5%）。此外，与血清SCC抗原相比，6-miRNA组合能够准确检测出OSCC的存在。目前的特异性miRNA组合可能成为口腔癌的一种新型候选生物标志物。
